Jill Everland Larsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1344064/publications.pdf

Version: 2024-02-01

46 papers 3,426 citations

201674 27 h-index 42 g-index

47 all docs

47 docs citations

times ranked

47

6761 citing authors

#	Article	IF	CITATIONS
1	An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. Neoplasia, 2020, 22, 294-310.	5.3	21
2	Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. Molecular Oncology, 2019, 13, 1503-1518.	4.6	17
3	Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Research, 2018, 78, 1986-1999.	0.9	13
4	Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance. International Journal of Cancer, 2017, 141, 614-620.	5.1	117
5	Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non–Small Cell Lung Cancers. Cancer Research, 2017, 77, 3070-3081.	0.9	36
6	Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties. Cancer Prevention Research, 2017, 10, 514-524.	1.5	9
7	PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis. Cancer Research, 2017, 77, 187-197.	0.9	55
8	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4
9	Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers. Journal of Thoracic Oncology, 2016, 11, 346-360.	1.1	11
10	Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non–Small Cell Lung Cancer and Its Potential as a Circulating Biomarker. Cancer Prevention Research, 2016, 9, 43-52.	1.5	33
11	ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. Journal of Clinical Investigation, 2016, 126, 3219-3235.	8.2	256
12	Nuclear Receptor Expression and Function in Human Lung Cancer Pathogenesis. PLoS ONE, 2015, 10, e0134842.	2.5	12
13	Molecular Basis of Lung Cancer. , 2015, , 475-490.e1.		1
14	Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5. Molecular Cancer Research, 2015, 13, 784-794.	3.4	35
15	Abstract A22: Differential MYC dependence in NSCLC identified through pharmacological and genetic MYC inhibition. , 2015, , .		O
16	Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells. Oncogene, 2014, 33, 5457-5466.	5.9	29
17	ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14788-14793.	7.1	205
18	Loss of miR125a Expression in a Model of K-ras–Dependent Pulmonary Premalignancy. Cancer Prevention Research, 2014, 7, 845-855.	1.5	5

#	Article	IF	Citations
19	Abstract 1855: SCT methylation is a potential cancer biomarker for lung cancer. , 2014, , .		O
20	Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer. Cell, 2013, 155, 552-566.	28.9	151
21	Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations. Molecular Cancer Research, 2013, 11, 638-650.	3.4	192
22	NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6524-6529.	7.1	84
23	NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition. Oncogenesis, 2013, 2, e63-e63.	4.9	21
24	Epithelial–mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis, 2012, 33, 1639-1646.	2.8	24
25	Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. Journal of the National Cancer Institute, 2012, 104, 228-239.	6.3	424
26	Array-Comparative Genomic Hybridization Reveals Loss of SOCS6 Is Associated with Poor Prognosis in Primary Lung Squamous Cell Carcinoma. PLoS ONE, 2012, 7, e30398.	2.5	28
27	Molecular Biology of Lung Cancer: Clinical Implications. Clinics in Chest Medicine, 2011, 32, 703-740.	2.1	194
28	Genes and Gene Ontologies Common to Airflow Obstruction and Emphysema in the Lungs of Patients with COPD. PLoS ONE, 2011, 6, e17442.	2.5	26
29	Genomic medicine in nonâ€small cell lung cancer: Paving the path to personalized care. Respirology, 2011, 16, 257-263.	2.3	18
30	Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy. Molecular Cancer Therapeutics, 2011, 10, 336-346.	4.1	151
31	Targeted Therapies for Lung Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 512-527.	2.0	91
32	SMAC Mimetic (JP1201) Sensitizes Non–Small Cell Lung Cancers to Multiple Chemotherapy Agents in an IAP-Dependent but TNF-α–Independent Manner. Cancer Research, 2011, 71, 7640-7648.	0.9	55
33	<i>ADAM28</i> : A potential oncogene involved in asbestosâ€related lung adenocarcinomas. Genes Chromosomes and Cancer, 2010, 49, 688-698.	2.8	24
34	MicroRNA-218 Is Deleted and Downregulated in Lung Squamous Cell Carcinoma. PLoS ONE, 2010, 5, e12560.	2.5	100
35	Aldehyde Dehydrogenase Activity Selects for Lung Adenocarcinoma Stem Cells Dependent on Notch Signaling. Cancer Research, 2010, 70, 9937-9948.	0.9	357
36	Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. European Respiratory Journal, 2010, 35, 152-159.	6.7	44

#	Article	IF	CITATIONS
37	Meta- and Pooled Analysis of GSTP1 Polymorphism and Lung Cancer: A HuGE-GSEC Review. American Journal of Epidemiology, 2009, 169, 802-814.	3.4	73
38	Expression profiling identifies genes involved in emphysema severity. Respiratory Research, 2009, 10, 81.	3.6	35
39	Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. European Respiratory Journal, 2007, 30, 21-26.	6.7	20
40	Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma. Clinical Cancer Research, 2007, 13, 2946-2954.	7.0	107
41	Myeloperoxidase G-463A polymorphism and lung cancer: A HuGE Genetic Susceptibility to Environmental Carcinogens pooled analysis. Genetics in Medicine, 2007, 9, 67-73.	2.4	47
42	Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis, 2006, 28, 760-766.	2.8	98
43	CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis, 2006, 27, 525-532.	2.8	66
44	Risk of non-small cell lung cancer and the cytochrome P4501A1 Ile462Val polymorphism. Cancer Causes and Control, 2005, 16, 579-585.	1.8	31
45	Re: Effects of N-(4-Hydroxy-phenyl)retinamide on hTERT Expression in the Bronchial Epithelium of Cigarette Smokers. Journal of the National Cancer Institute, 2002, 94, 949-a-950.	6.3	4
46	Pax gene diversity in the basal cnidarian Acropora millepora (Cnidaria, Anthozoa): Implications for the evolution of the Pax gene family. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4475-4480.	7.1	102